Protocol for a systematic review and meta-analysis: the effects of atorvastatin on interleukin-1β (IL-1β) levels in patients
Open Access
- 10 November 2026
- journal article
- review article
- Published by Wolters Kluwer Health in International Journal of Surgery Protocols
Abstract
Background: Atorvastatin is a lipophilic 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor with potential pleiotropic anti-inflammatory effects. Interleukin-1β (IL-1β) is a pro-inflammatory cytokine implicated in cardiovascular, metabolic, and autoimmune diseases. However, evidence regarding the effect of atorvastatin on IL-1β concentrations is inconsistent. Objective: To systematically evaluate the effect of atorvastatin on IL-1β concentrations in human participants. Methods: This protocol follows PRISMA-P guidelines. We will search PubMed, Scopus, Web of Science, and Embase for English-language, peer-reviewed studies published from January 2005 through October 2025. Eligible studies will include randomized controlled trials, controlled non-randomized studies, and uncontrolled longitudinal before-after studies of atorvastatin monotherapy that report IL-1β at baseline and follow-up, change scores, or comparable endline values in the intervention and comparator groups. We will synthesize results separately by study design and comparator structure. If appropriate after assessing clinical and methodological comparability, we will conduct cross-design synthesis only as an exploratory analysis. Mean differences (MD) or standardized mean differences (SMD) will be pooled using random-effects models. We will assess heterogeneity using I 2 and evaluate the certainty of the evidence using GRADE. Outcomes: We will estimate whether atorvastatin changes IL-1β concentrations and explore whether the dose, treatment duration, clinical condition, study design, and assay method modify the estimated effect. Ethics and dissemination: Ethical approval is not required because we will use only publiclyavailable data. We will submit findings to a peer-reviewed journaland present them at scientific meetings.Keywords
This publication has 29 references indexed in Scilit:
- Statins: Novel Approaches for the Management of Doxorubicin-Induced Cardiotoxicity—A Literature ReviewCardiovascular Toxicology, 2025
- Atorvastatin attenuates the expression of damage-associated molecular patterns and inflammatory cytokines in patients with psoriasisPharmacological Reports, 2025
- The effect of atorvastatin on the concentrations of methylglyoxal, glyoxalase 1, and aldo–keto reductase family 1 member B10 in patients with type 2 diabetes mellitus and prediabetesInternational Journal of Diabetes in Developing Countries, 2023
- Some pleiotropic effects of statins on hepatocellular carcinoma cells: Comparative study on atorvastatin, rosuvastatin and simvastatinAdvances in Medical Sciences, 2023
- Atorvastatin-mediated inhibition of prenylation of Rab27b and Rap1a in platelets attenuates their prothrombotic capacity and modulates clot structurePlatelets, 2023
- Understanding the molecular mechanisms of statin pleiotropic effectsArchives of Toxicology, 2023
- Targeting interleukin‐β by plant‐derived natural products: Implications for the treatment of atherosclerotic cardiovascular diseasePhytotherapy Research, 2021
- Lipid and pleotropic effects of atorvastatin therapy and its combination with ezetimibe in patients with coronary artery disease and diabetesAtherosclerosis, 2014
- Effect of interferon-β and atorvastatin on Th1/Th2 cytokines in multiple sclerosisNeurochemistry International, 2008
- Changes in Flow-Mediated Dilatation, Cytokines and Carotid Arterial Stenosis During Aggressive Atorvastatin Treatment in Normocholesterolemic PatientsJournal of the Chinese Medical Association, 2005